Developer docs
API playgroundTry for free, no card

Search company profiles

Barricaid

Full company profile

uuid0000anu

Namestring
Barricaid
Legal namestring
Intrinsic Therapeutics, Inc.
Websiteurl
barricaid.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Barricaid (legal entity Intrinsic Therapeutics, Inc.) is a privately held medical device company headquartered in Woburn, Massachusetts, founded in 1999 by Greg Lambrecht. The company developed and commercializes the Barricaid Annular Closure Device (ACD), a bone-anchored implant designed to seal large annular defects created during lumbar discectomy surgery in order to reduce the risk of recurrent disc herniation and the need for reoperation. The technology consists of a bone anchor (a jagged/mesh component that engages vertebral bone) and a polyester flap (woven fabric that seals the defect), and is MR Conditional at 1.5-Tesla and 3-Tesla. The device received FDA Pre-Market Approval in 2019 following a multicenter Level I randomized controlled trial, with five-year follow-up results published in JAMA Network Open.

Barricaid sells primarily through one-time hardware sales of the implant to hospitals and ambulatory surgical centers (ASCs), with pricing determined through facility agreements and payer contracts. A new Category I CPT code (63032), effective January 1, 2026, supplements the existing HCPCS code C9757 (CMS, 2020) and standardizes reimbursement. Coverage extends to Medicare, Cigna, the Veterans Administration (covering roughly 9 million lives), and more than 20 commercial insurers. The company maintains a direct U.S. field sales organization led by VP Sales East and VP Sales West, supported by Territory Managers and Clinical Specialists, and operates a Centers of Excellence program (Platinum and Gold tiers) to recognize high-volume adopters.

The company is led by President and CEO Keith Valentine (appointed April 2025), a spine industry veteran from NuVasive, Medtronic Spine & Biologics, and SeaSpine. The board is chaired by Ryan Drant (Founder and Managing Partner of Questa Capital). The product portfolio includes the core Barricaid Annular Closure Device and the Barricaid Narrow Anchor Device, a 25%-smaller variant announced for March 2026 release. As of October 2025, nearly 13,000 patients had been implanted with Barricaid, supported by clinical evidence across eight distinct patient populations. The company is backed by Questa Capital, New Enterprise Associates, Greenspring Associates, Quadrille Capital, Delos Capital, and CRG, among others, with cumulative disclosed funding exceeding $300 million across multiple rounds.

Short descriptiontext

Barricaid (Intrinsic Therapeutics) develops the FDA PMA-approved bone-anchored annular closure implant, sealing annular defects during lumbar discectomy to prevent reherniation. The privately held medical device company sells directly to U.S. hospitals and ambulatory surgical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
annular closure device, lumbar discectomy implant, spine medical device, bone-anchored prosthesis, disc reherniation prevention
Industry1 code
PRIMARYHLAHAEAC
Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Spinal Implants
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales - Barricaid Implant
TypeHardware Sales
Description

One-time device sale for each surgical implantation procedure. The Barricaid annular closure device is sold to hospitals and ambulatory surgical centers (ASCs) for use in lumbar discectomy procedures. Revenue is procedure-based with each implant representing a transaction. Pricing is not publicly disclosed and varies based on facility agreements and payer contracts.

barricaid.com
2Professional Training Services
TypeProfessional Services
Description

Company provides surgeon training, proctoring, and educational programs for adoption of the Barricaid procedure. These programs support the core device sales while building surgeon expertise and network.

barricaid.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Barricaid is a bone-anchored annular closure device (ACD) implanted during lumbar discectomy surgery to seal large annular defects and prevent disc reherniation. The system consists of a jagged/mesh bone anchor that inserts into vertebral bone and a woven polyester flap that closes the defect left after discectomy. It is the only FDA PMA-approved bone-anchored ACD, demonstrated in a Level I RCT (published in JAMA with five-year follow-up) to reduce reoperations for reherniations by 81% in patients with large annular defects.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 81% reduction in reoperations for reherniations in patients with large annular defects
+3 more records
Product overview1 text field

Barricaid is a proprietary annular closure medical device portfolio consisting of the core Barricaid Annular Closure Device (a bone-anchored implant) and its newer variant, the Barricaid Narrow Anchor Device (25% smaller). Both products are designed to reduce reoperations for reherniations in lumbar discectomy patients with large annular defects. The devices are implanted during discectomy surgery and do not require additional incisions.

Product and service2 records
1Barricaid Annular Closure Device
CategoryAnnular Closure Device
Description

Bone-anchored annular closure implant designed to reduce reherniation and reoperation rates in patients with large annular defects following lumbar discectomy surgery. Sold to hospitals and ambulatory surgical centers (ASCs) for use by spine surgeons.

2Barricaid Narrow Anchor Device
CategoryAnnular Closure Device
Description

A 25% smaller version of the standard Barricaid anchor, designed to facilitate implantation and reduce nerve root retraction during lumbar discectomy procedures. The device has passed standard mechanical tests and follows regulatory and clinical momentum including new CPT coding.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1American Medical Association (AMA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

AMA CPT Editorial Panel created new Category I CPT code 63032 for bone-anchored annular closure, effective January 1, 2026. This milestone enables surgeons to code specifically for Barricaid procedure, increasing patient access.

barricaid.com
2International Society for the Advancement of Spine Surgery (ISASS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-19
Description

ISASS issued 2025 recommendations and coverage criteria for Barricaid bone-anchored annular closure. ISASS policy guidance supports coverage for appropriately selected patient populations.

barricaid.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-20
Description

Cigna Healthcare issued positive coverage policy for Barricaid Bone-Anchored Annular Closure device. Cigna represents one of the five largest commercial payors in the U.S.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

VA added HCPCS code C9757 (Barricaid Implantation) to their 2021 national outpatient fee schedule. VA covers approximately 9 million lives as the 2nd largest government-funded health insurance organization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

CMS established new HCPCS code C9757 for Barricaid device, included in Medicare hospital outpatient and ASC national fee schedules effective January 1, 2020. Provides standard payment pathway for the technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Relievant developed the Intracept procedure for vertebrogenic pain and was acquired by Boston Scientific in 2023. It targets the same interventional spine specialist with a procedure-based implant and CPT code strategy analogous to Barricaid's commercial playbook.

TypeBroad incumbent
Description

Medtronic is the largest spine medical device company globally with a broad lumbar portfolio. Barricaid's CEO Keith Valentine previously held VP Marketing roles at Medtronic Spine & Biologics, and Medtronic's BMP/INFUSE franchise competes in the same discectomy and fusion-adjacent surgical workflow.

TypeBroad incumbent
Description

Globus Medical acquired NuVasive in 2023, creating the largest pure-play spine medical device company. Barricaid's CEO and sales leadership all came from NuVasive, and NuVasive's broader lumbar portfolio overlaps with the discectomy-adjacent workflow Barricaid targets.

TypeDirect peer
Description

ATEC is a pure-play spine company focused on procedurally-integrated solutions for the operating spine surgeon. ATEC sells a portfolio of lateral and minimally invasive lumbar products to the same hospital and ASC customers Barricaid targets, making it a comparable sized direct competitor.

TypeDirect peer
Description

Spine Wave is a privately held spine medical device company that sells a portfolio of lumbar and cervical products including discectomy-related solutions. It targets the same spine surgeon customer base with similar procedure-based hardware sales.

TypeDirect peer
Description

Implanet is a European-listed spine medical device company offering lumbar and cervical implant solutions. It serves the same discectomy-adjacent procedural workflow Barricaid targets, though primarily in Europe where Barricaid is not currently sold.

TypeDirect peer
Description

SI-BONE is a focused spine medical device company of similar size to Barricaid that sells procedure-based implants (iFuse for sacroiliac joint dysfunction) directly to spine surgeons via a similar field-sales and reimbursement-led model. Barricaid's VP Health Economics April Spillane previously led outpatient divisions at SI-BONE.

TypeDirect peer
Description

Vertos Medical developed minimally invasive treatments for lumbar spinal stenosis and was acquired by Stryker in 2024. Vertos competed in the same lumbar interventional space targeting referring spine specialists as Barricaid.

TypeDirect peer
Description

Orthofix merged with SeaSpine in 2023 to form a focused spine and biologics company. Both Barricaid's CEO (Keith Valentine, ex-SeaSpine CEO) and its VP Sales East/West came directly from Orthofix/SeaSpine, and the company sells competing lumbar procedural solutions to the same spine surgeons.

TypeBroad incumbent
Description

Stryker is a diversified medtech incumbent with a large spine and orthopedics division. Barricaid's founder Greg Lambrecht was previously VP at Stryker, and Stryker competes broadly in the same hospital and ASC surgical channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Barricaid

Spinal Implantsbarricaid.com

Barricaid (Intrinsic Therapeutics) develops the FDA PMA-approved bone-anchored annular closure implant, sealing annular defects during lumbar discectomy to prevent reherniation. The privately held medical device company sells directly to U.S. hospitals and ambulatory surgical centers.

What Barricaid does

Barricaid (legal entity Intrinsic Therapeutics, Inc.) is a privately held medical device company headquartered in Woburn, Massachusetts, founded in 1999 by Greg Lambrecht. The company developed and commercializes the Barricaid Annular Closure Device (ACD), a bone-anchored implant designed to seal large annular defects created during lumbar discectomy surgery in order to reduce the risk of recurrent disc herniation and the need for reoperation. The technology consists of a bone anchor (a jagged/mesh component that engages vertebral bone) and a polyester flap (woven fabric that seals the defect), and is MR Conditional at 1.5-Tesla and 3-Tesla. The device received FDA Pre-Market Approval in 2019 following a multicenter Level I randomized controlled trial, with five-year follow-up results published in JAMA Network Open.

Barricaid sells primarily through one-time hardware sales of the implant to hospitals and ambulatory surgical centers (ASCs), with pricing determined through facility agreements and payer contracts. A new Category I CPT code (63032), effective January 1, 2026, supplements the existing HCPCS code C9757 (CMS, 2020) and standardizes reimbursement. Coverage extends to Medicare, Cigna, the Veterans Administration (covering roughly 9 million lives), and more than 20 commercial insurers. The company maintains a direct U.S. field sales organization led by VP Sales East and VP Sales West, supported by Territory Managers and Clinical Specialists, and operates a Centers of Excellence program (Platinum and Gold tiers) to recognize high-volume adopters.

The company is led by President and CEO Keith Valentine (appointed April 2025), a spine industry veteran from NuVasive, Medtronic Spine & Biologics, and SeaSpine. The board is chaired by Ryan Drant (Founder and Managing Partner of Questa Capital). The product portfolio includes the core Barricaid Annular Closure Device and the Barricaid Narrow Anchor Device, a 25%-smaller variant announced for March 2026 release. As of October 2025, nearly 13,000 patients had been implanted with Barricaid, supported by clinical evidence across eight distinct patient populations. The company is backed by Questa Capital, New Enterprise Associates, Greenspring Associates, Quadrille Capital, Delos Capital, and CRG, among others, with cumulative disclosed funding exceeding $300 million across multiple rounds.

Barricaid firmographics

Firmographics
Name
Barricaid
Legal name
Intrinsic Therapeutics, Inc.
Website
https://barricaid.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
51–100 employees
Short description
Barricaid (Intrinsic Therapeutics) develops the FDA PMA-approved bone-anchored annular closure implant, sealing annular defects during lumbar discectomy to prevent reherniation. The privately held medical device company sells directly to U.S. hospitals and ambulatory surgical centers.
Ownership category
akta.pro rank

Barricaid industry classification

Industry
Product category
Spinal Implants
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAC
Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Annular closure device
  • Lumbar discectomy implant
  • Spine medical device
  • Bone-anchored prosthesis
  • Disc reherniation prevention

Where Barricaid is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Barricaid business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Medical Device Sales - Barricaid Implant: One-time device sale for each surgical implantation procedure. The Barricaid annular closure device is sold to hospitals and ambulatory surgical centers (ASCs) for use in lumbar discectomy procedures. Revenue is procedure-based with each implant representing a transaction. Pricing is not publicly disclosed and varies based on facility agreements and payer contracts.
  2. Professional Training Services: Company provides surgeon training, proctoring, and educational programs for adoption of the Barricaid procedure. These programs support the core device sales while building surgeon expertise and network.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Barricaid product offering

Product offering

Core offering

Barricaid is a bone-anchored annular closure device (ACD) implanted during lumbar discectomy surgery to seal large annular defects and prevent disc reherniation. The system consists of a jagged/mesh bone anchor that inserts into vertebral bone and a woven polyester flap that closes the defect left after discectomy. It is the only FDA PMA-approved bone-anchored ACD, demonstrated in a Level I RCT (published in JAMA with five-year follow-up) to reduce reoperations for reherniations by 81% in patients with large annular defects.

Product overview

Barricaid is a proprietary annular closure medical device portfolio consisting of the core Barricaid Annular Closure Device (a bone-anchored implant) and its newer variant, the Barricaid Narrow Anchor Device (25% smaller). Both products are designed to reduce reoperations for reherniations in lumbar discectomy patients with large annular defects. The devices are implanted during discectomy surgery and do not require additional incisions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Barricaid Annular Closure Device Bone-anchored annular closure implant designed to reduce reherniation and reoperation rates in patients with large annular defects following lumbar discectomy surgery. Sold to hospitals and ambulatory surgical centers (ASCs) for use by spine surgeons.
  • Barricaid Narrow Anchor Device A 25% smaller version of the standard Barricaid anchor, designed to facilitate implantation and reduce nerve root retraction during lumbar discectomy procedures. The device has passed standard mechanical tests and follows regulatory and clinical momentum including new CPT coding.

Quantifiable outcome

  • 81% reduction in reoperations for reherniations in patients with large annular defects
  • +3 more outcomes

Companies that use Barricaid

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Barricaid technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Barricaid partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • American Medical Association (AMA)coreStrategic or Co-development Partner · 24 October 2025AMA CPT Editorial Panel created new Category I CPT code 63032 for bone-anchored annular closure, effective January 1, 2026. This milestone enables surgeons to code specifically for Barricaid procedure, increasing patient access.
  • International Society for the Advancement of Spine Surgery (ISASS)coreStrategic or Co-development Partner · 19 June 2025ISASS issued 2025 recommendations and coverage criteria for Barricaid bone-anchored annular closure. ISASS policy guidance supports coverage for appropriately selected patient populations.
  • Cigna HealthcarecoreStrategic or Co-development Partner · 20 June 2023Cigna Healthcare issued positive coverage policy for Barricaid Bone-Anchored Annular Closure device. Cigna represents one of the five largest commercial payors in the U.S.
  • Veterans Administration (VA)majorStrategic or Co-development Partner · 1 January 2021VA added HCPCS code C9757 (Barricaid Implantation) to their 2021 national outpatient fee schedule. VA covers approximately 9 million lives as the 2nd largest government-funded health insurance organization.
  • Centers for Medicare & Medicaid Services (CMS)coreStrategic or Co-development Partner · 1 January 2020CMS established new HCPCS code C9757 for Barricaid device, included in Medicare hospital outpatient and ASC national fee schedules effective January 1, 2020. Provides standard payment pathway for the technology.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Barricaid competitors and assessment

Company assessment

Emerging players

  • Relievant Medsystems (Boston Scientific): Relievant developed the Intracept procedure for vertebrogenic pain and was acquired by Boston Scientific in 2023. It targets the same interventional spine specialist with a procedure-based implant and CPT code strategy analogous to Barricaid's commercial playbook.

Broad incumbents

  • Medtronic Spine & Biologics: Medtronic is the largest spine medical device company globally with a broad lumbar portfolio. Barricaid's CEO Keith Valentine previously held VP Marketing roles at Medtronic Spine & Biologics, and Medtronic's BMP/INFUSE franchise competes in the same discectomy and fusion-adjacent surgical workflow.
  • NuVasive (now Globus Medical): Globus Medical acquired NuVasive in 2023, creating the largest pure-play spine medical device company. Barricaid's CEO and sales leadership all came from NuVasive, and NuVasive's broader lumbar portfolio overlaps with the discectomy-adjacent workflow Barricaid targets.
  • Stryker Spine: Stryker is a diversified medtech incumbent with a large spine and orthopedics division. Barricaid's founder Greg Lambrecht was previously VP at Stryker, and Stryker competes broadly in the same hospital and ASC surgical channels.

Direct peers

  • Alphatec Spine (ATEC): ATEC is a pure-play spine company focused on procedurally-integrated solutions for the operating spine surgeon. ATEC sells a portfolio of lateral and minimally invasive lumbar products to the same hospital and ASC customers Barricaid targets, making it a comparable sized direct competitor.
  • Spine Wave: Spine Wave is a privately held spine medical device company that sells a portfolio of lumbar and cervical products including discectomy-related solutions. It targets the same spine surgeon customer base with similar procedure-based hardware sales.
  • Implanet: Implanet is a European-listed spine medical device company offering lumbar and cervical implant solutions. It serves the same discectomy-adjacent procedural workflow Barricaid targets, though primarily in Europe where Barricaid is not currently sold.
  • SI-BONE: SI-BONE is a focused spine medical device company of similar size to Barricaid that sells procedure-based implants (iFuse for sacroiliac joint dysfunction) directly to spine surgeons via a similar field-sales and reimbursement-led model. Barricaid's VP Health Economics April Spillane previously led outpatient divisions at SI-BONE.
  • Vertos Medical (Stryker): Vertos Medical developed minimally invasive treatments for lumbar spinal stenosis and was acquired by Stryker in 2024. Vertos competed in the same lumbar interventional space targeting referring spine specialists as Barricaid.
  • Orthofix / SeaSpine: Orthofix merged with SeaSpine in 2023 to form a focused spine and biologics company. Both Barricaid's CEO (Keith Valentine, ex-SeaSpine CEO) and its VP Sales East/West came directly from Orthofix/SeaSpine, and the company sells competing lumbar procedural solutions to the same spine surgeons.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Barricaid social profiles

Digital presence

Barricaid compliance and trust

Trust signal

Compliance3 records

Barricaid financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Barricaid leadership team

Management profile

Number of profiles

Profiles15 records

Barricaid funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Barricaid M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barricaid

What does Barricaid do?

Barricaid is a bone-anchored annular closure device (ACD) implanted during lumbar discectomy surgery to seal large annular defects and prevent disc reherniation. The system consists of a jagged/mesh bone anchor that inserts into vertebral bone and a woven polyester flap that closes the defect left after discectomy. It is the only FDA PMA-approved bone-anchored ACD, demonstrated in a Level I RCT (published in JAMA with five-year follow-up) to reduce reoperations for reherniations by 81% in patients with large annular defects.

Is Barricaid a public or private company?

Barricaid is a private company. It is classified as venture growth investor backed and is currently operating.

When was Barricaid founded?

Barricaid was founded in 1999. It employs 51 to 100 people.

Where is Barricaid based?

Barricaid is headquartered in Woburn, United States, in the North America region.

How does Barricaid make money?

Two revenue lines are on record. Medical Device Sales - Barricaid Implant is the primary driver. The others are professional Training Services.

Who are Barricaid's main competitors?

Relievant Medsystems (Boston Scientific) is listed as an emerging player. Broad incumbents are Medtronic Spine & Biologics, NuVasive (now Globus Medical) and Stryker Spine. Direct peers are Alphatec Spine (ATEC), Spine Wave, Implanet, SI-BONE, Vertos Medical (Stryker) and Orthofix / SeaSpine.

Does Barricaid have an API?

No public API is recorded for Barricaid.

What industry is Barricaid in?

Barricaid's product category is Spinal Implants. Its primary akta.pro industry code is HLAHAEAC, Spine Implants & Motion Preservation (Fusion/Disc/Interspinous). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KRGVMedical Breakthroughs: Undergoing barricaid surgery to relieve back painThe U.S. Food and Drug Administration (FDA) has approved the Barricaid device, a new technology designed to prevent re-herniation and reduce the need for repeat surgeries following lumbar discectomy procedures. Clinical studies indicate that patients using this device have an 81% chance of avoiding a second surgery, addressing a significant complication rate where 30 to 40 percent of previous patients required additional operations.PR NewswireLumbar Disc Herniation Market is Projected to Reach USD 7.2 Billion by 2036 as Novel Therapies and Minimally Invasive Treatments are Gaining Momentum | DelveInsightDelveInsight published a market report projecting the lumbar disc herniation market to grow from USD 6.1 billion in 2025 to USD 7.2 billion by 2036 in the 7MM (United States, EU4, United Kingdom, and Japan), driven by emerging therapies and minimally invasive treatments. The United States accounts for approximately 42% of the market. Key recent developments include SpinaFX Medical receiving FDA Investigational Device Exemption for its Triojection device, Seikagaku Corporation resubmitting its Biologics License Application for Condoliase to the US FDA, and Intrinsic Therapeutics launching an updated Barricaid annular closure device.SouthlakestyleSouthlake-Area Top Doc Earns National RecognitionDr. Michael Briseño has received a Barricaid® Platinum Center of Excellence designation from Intrinsic Therapeutics, Inc., recognizing clinical excellence in high-risk lumbar discectomy procedures. The designation highlights the use of the Barricaid device, which Intrinsic Therapeutics claims reduces the risk of repeat surgery for reherniation by 81%. This recognition underscores the commitment of Dr. Briseño's practice teams at North Texas Orthopedic & Spine Center and Texas Health Orthopedic & Spine Surgery Center Heritage to evidence-based care.PR NewswireIntrinsic Therapeutics Announces Initial Release of Its Next Generation Barricaid Narrow Anchor Device Designed to Reduce Reherniation After Back SurgeryIntrinsic Therapeutics, Inc. announced the initial release of its Barricaid Narrow Anchor, a next-generation version of its FDA PMA-approved annular closure device that is 25 percent smaller than the standard anchor (reduced from 8mm to 6mm width). The new device is designed to reduce reherniation and reoperation rates following lumbar discectomy by making implantation easier, reducing bony removal, and decreasing nerve root retraction by 25 to 40 percent. The launch follows the American Medical Association's inclusion of a new CPT code for bone-anchored annular closure in the 2026 code set, effective January 1, 2026.PR NewswireIntrinsic Therapeutics Announces the First Endoscopic Barricaid Implantation in the Great Lakes Region by Dr. Nick NenadovichIntrinsic Therapeutics announced the first endoscopic Barricaid implantation in the Great Lakes Region, performed by Dr. Nick Nenadovich using Amplify Surgical's dualPortal endoscopic approach. The procedure represents a milestone in adopting the Barricaid Bone-Anchored Annular Closure Device, which clinical studies show reduces reoperations for reherniations by 81% in lumbar discectomy patients. A new Category I CPT Code for bone-anchored annular closure will take effect on January 1, 2026.PR NewswireIntrinsic Therapeutics Announces that AMA Released CPT 2026 Code Set Including New CPT Code 63032 Describing Bone-Anchored Annular Closure, Effective January 1, 2026Intrinsic Therapeutics announced that the American Medical Association (AMA) has published a new Category I CPT code (63032) for bone-anchored annular closure, effective January 1, 2026. The add-on code specifically describes the adjunctive placement of the Barricaid annular closure device following lumbar discectomy in patients with large annular defects. With ISASS 2025 guidelines now recommending annular closure for appropriately selected patients, Intrinsic is urging surgeons and payors nationwide to update their systems to include this new reimbursement code.PR NewswireIntrinsic Therapeutics Announces the First Implantation of the Barricaid® Annular Closure Device Under Awake SedationIntrinsic Therapeutics announced that its Barricaid Annular Closure Device was successfully implanted for the first time in several patients under awake sedation without general anesthesia, performed by neurosurgeon Dr. Ernest E. Braxton Jr. in Vail, Colorado. The awake surgery technique allows real-time patient communication during the procedure, faster recovery, and reportedly reduces the risk of reherniation and subsequent fusion surgeries compared to traditional lumbar discectomy. The company stated that growing clinical acceptance is demonstrating Barricaid's compatibility with most discectomy approaches for indicated patients.PR NewswireIntrinsic Therapeutics Appoints Industry Veterans Mike Lytle and Dave Decker to Lead Sales and Advance Discectomy TreatmentIntrinsic Therapeutics, a Boston-based medical technology company, announced the appointment of Mike Lytle as Vice President of Sales, West and Dave Decker as Vice President of Sales, East, to drive commercial expansion of its Barricaid Annular Closure Device. Both executives bring over 30 years of spine and orthopedics experience, having previously held senior roles at NuVasive and SeaSpine/Orthofix. The Barricaid device, designed to reduce reoperations for reherniations following lumbar discectomy, has been implanted in over 12,000 patients.PR NewswireIntrinsic Therapeutics Announces the First Implantation of the Barricaid® Annular Closure Device via Endoscopic ApproachIntrinsic Therapeutics announced the first implantation of its Barricaid Annular Closure Device via an endoscopic approach, performed by Dr. Daniel E. Choi at Gramercy Surgery Center in New York using Amplify Surgical's dualPortal system. The procedure represents a new integration of endoscopic spine surgery technology with the Barricaid device, which is designed to reduce reoperations for reherniations by 81%. Intrinsic's CTO noted the integration required no changes to instruments or procedural steps, enabling surgeons who prefer endoscopic approaches to maintain discectomy outcomes while reducing reherniation risk.